0.04
-0.015(-27.27%)
Currency In USD
Address
201 Elliott Avenue West
Seattle, WA 98119
United States of America
Phone
206 568 1466
Website
Sector
Healthcare
Industry
Biotechnology
Employees
160
First IPO Date
April 23, 2021
| Name | Title | Pay | Year Born |
| Mr. Leonard S. Paolillo | Interim President & Chief Executive Officer | 523,967 | 1979 |
| Dr. John H. Leaman M.D. | Chief Financial & Bus. Officer | 964,365 | 1973 |
| Dr. Stephen Bevan Shrewsbury M.B. Ch.B., M.D. | Chief Medical Officer | 0 | 1957 |
| Ms. Jennifer L. Berman | Vice President of Marketing | 0 | N/A |
| Ms. Sarah Wille | Vice President of Human Resources | 0 | N/A |
| Dr. John D. Hoekman Ph.D. | Co-Founder and Chief Technology & Development Officer | 0 | 1981 |
| Mr. Michael W. Kalb CPA | Chief Financial Officer | 0 | 1971 |
| Dr. Lynn C. Gold Ph.D. | Senior Vice President of Regulatory | 0 | 1957 |
| Mr. Scott Youmans | Senior Vice President of Technical Operations | 0 | 1967 |
| Ms. Patty Billingsley | Vice President of Sales | 0 | N/A |
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.